https://www.selleckchem.com/products/loxo-292.html
Early immunological biomarkers that predict rejection and chronic allograft loss are needed to inform preemptive therapy and improve long-term outcomes. Here, we prospectively examined the ratio of interleukin-10 (IL-1 to tumor necrosis factor-α (TNFα) produced by transitional-1 B cells (T1 3 months after transplantation as a predictive biomarker for clinical and subclinical renal allograft rejection and subsequent clinical course. In both Training (n = 162) and Internal Validation (n = 82) Sets, the T1B IL-10/TNFα ratio 3 months a
Gusto
Magkomento
Ibahagi
